Drug Profile
Lorcaserin - Epygenix Therapeutics/University of California at San Fransisco
Alternative Names: EPX 200Latest Information Update: 07 Sep 2022
Price :
$50
*
At a glance
- Originator University of California at San Francisco
- Developer Epygenix Therapeutics; University of California at San Francisco; University of Colorado at Denver
- Class Antiepileptic drugs; Benzazepines; Obesity therapies; Small molecules
- Mechanism of Action Serotonin 2C receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Dravet syndrome; Lennox-Gastaut syndrome
Most Recent Events
- 07 Sep 2022 Phase-II clinical trials in Lennox-Gastaut syndrome in USA (unspecified route) (Epygenix Therapeutics pipeline, July 2022)
- 07 Sep 2022 Loracaserin receives Rare Paediatric Disease Designation from US FDA for Lennox-Gastaut Syndrome prior to September 2022 (Epygenix Therapeutics pipeline, September 2022)
- 18 Jul 2022 Epygenix Therapeutics announces intention to submit an IND application with the regulatory bodies for Dravet syndrome and Lennox-Gastaut syndrome (Epygenix Therapeutics pipeline, July 2022)